Ambrisentan

Idiopathic pulmonary fibrosis ( IPF ) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause occurring in...


The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension are published in the European Heart Journal and...


Activation of the endothelin system has been demonstrated in both plasma and lung tissue of PAH ( pulmonary arterial hypertension...


Ambrisentan ( US: Letairis; EU: Volibris ) is an oral selective endothelin receptor antagonist licensed for use in pulmonary arterial...


Present guidelines for the diagnosis of idiopathic pulmonary fibrosis require histological confirmation of surgical lung biopsy samples when high-resolution CT...


Data of the first phase IIIb/IV study, AMBITION, were presented at the ERS International Congress 2014. The study has investigated...


The FDA ( Food and Drug Administration ) has approved Letairis ( Ambrisentan ) for the treatment of pulmonary arterial...